The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
May 1st 2024
The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.
FDA Approves Alexion's Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder
March 25th 2024The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.
Susceptibility-Weighted Imaging Features Show Promise in Distinguishing AQP4-Negative-NMOSD From MS
February 17th 2024A recent study highlighted the potential of susceptibility-weighted image features as imaging biomarkers to differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder.
Health Canada Approves Inebilizumab as Treatment for Neuromyelitis Optica Spectrum Disorder
January 26th 2024In recent news, Health Canada approved inebilizumab for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive, using results from the N-MOmentum trial as the basis for the approval.
Long-term Tocilizumab Therapy Effective in Regulating Lymphocytes and Neutrophils in NMOSD
January 25th 2024A recent analysis revealed a reduction in regulatory lymphocyte subsets in patients with NMOSD before tocilizumab therapy, with subsequent restoration to normal levels after 1 year treatment.
Study Reveals Significant Up-Regulation of Potentially Disease-Specific Long Noncoding RNAs in NMOSD
January 23rd 2024In a recent study, investigators observed a substantial up-regulation of long noncoding RNAs among patients with neuromyelitis optica spectrum disorder in comparison with heathy individuals.
Vitamin D Deficiency Observed in Neuromyelitis Optica Spectrum Disorder
January 11th 2024A recent analysis revealed patients with neuromyelitis optica spectrum disorder exhibited significantly lower vitamin D levels, suggesting a potential association with impaired immune tolerance in the disorder.
Study Reveals Reasons for Increased Hospital Readmission Rates in NMOSD
January 9th 2024A recent study identified specific risk factors influencing readmission odds in patients with neuromyelitis optica spectrum disorder, contributing valuable insights for predictive algorithms and improved patient outcomes.
Susceptibility-Based Imaging Accurately Differentiates Pediatric-Onset MS From MOGAD
January 6th 2024A recent study revealed that susceptibility-based imaging can effectively differentiate pediatric-onset multiple sclerosis from pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Significant Demographic and Clinical Differences Observed in Patterns Between NMOSD and MS
December 17th 2023A recent meta-analysis revealed significant differences in characteristic between patients with NMOSD and MS, highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.
NMOSD Treatment Inebilizumab Maintains Efficacy in Asian Patients
December 16th 2023A recent subgroup analysis of the N-MOmentum study revealed that inebilizumab had equal efficacy in reducing attacks among Asian and nonAsian patients with NMOSD, demonstrating its continued superiority over placebo.
IL-6 Inhibitor Tocilizumab Effective in Treating NMOSD, Meta-Analysis Suggests
November 15th 2023A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.
The Payor Dilemma With Accessing Effective Therapies for NMOSD: Bruce Cree, MD, PhD, MAS, FAAN
November 4th 2023The clinical research director of the UCSF Multiple Sclerosis Center talked about challenges in accessibility for the 3 approved therapies for NMOSD caused by third-party payor resistance as well as the importance of educating clinicians about the effectiveness of inebilizumab. [WATCH TIME: 3 minutes]
Long-Term Benefits of Inebilizumab Revealed in N-MOmentum Analysis: Bruce Cree, MD, PhD, MAS, FAAN
October 13th 2023The clinical research director of the UCSF Multiple Sclerosis Center talked about a clinical trial highlighting the therapeutic benefits of longterm treatment with inebilizumab in patients with NMOSD. [WATCH TIME: 4 minutes]
Satralizumab Continues to Show Long-Term Efficacy in AQP4-IgG-Seropositive NMOSD
October 12th 2023A new analysis of the SAkuraMoon study showed that annual relapse rate remained consistently low in satralizumab-treated patients, with high proportions of patients remaining free from relapse, severe relapse, and worsening in disability.
Compliment C5 Inhibitors in NMOSD Safe Following Rituximab Use
October 11th 2023A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.
Clinical Insights on the Emerging Trends in Research for NMOSD and MOGAD
September 29th 2023Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.